Waite L M, Broe G A, Grayson D A, Creasey H
Centre for Education and Research on Ageing, Concord Hospital C25, University of Sydney, NSW 2139, Australia.
J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):296-302. doi: 10.1136/jnnp.71.3.296.
To identify if preclinical syndromes for Alzheimer's disease, vascular dementia, and Parkinson's disease and related dementias exist. Identification of dementia at early or even preclinical stages has important implications for treatment.
A community dwelling sample of 647 subjects aged 75 and over at recruitment were followed up for a mean period of 3.19 years (range 2.61 to 4.51 years). Each subject was asked to participate in a medical assessment which included a standardised medical history examining both past and current health and medication usage; a neuropsychological battery (mini mental state examination, Reid memory test, verbal fluency, subsets of the Boston naming test and similarities, clock drawing and copied drawings) and physical examination. Preclinical syndromes for the three predominant dementias (Alzheimer's disease, vascular dementia and Parkinson's disease, and related dementias) and their combinations were defined using cognitive, motor, and vascular features. Their longitudinal outcome as defined by death and dementia incidence was examined.
Preclinical syndromes affected 55.7% (n=299) of subjects. Preclinical syndromes showed a trend for an increased odds of death (odds ratio 1.72, p=0.056) and a significantly increased odds of developing dementia (odds ratio 4.81, p<0.001). Preclinical syndromes were highly sensitive, detecting 52 of 58 (89.7%) incident dementias. Two hundred and sixteen of 268 (80.6%) preclinical subjects did not show dementia over the 3 year period (positive predictive value 19.4%). Subjects defined as having a combination of cognitive, extrapyramidal, and vascular features were at greatest risk of progressing to dementia.
Preclinical syndromes were sensitive and significant predictors of dementia. In view of their poor positive predictive value, the preclinical syndromes as defined in this study remain a research tool needing both definitional refinement and greater periods of observation. Multiple coexistent preclinical disorders resulted in a greater incidence of dementia, providing evidence for an additive role between multiple disorders.
确定阿尔茨海默病、血管性痴呆、帕金森病及相关痴呆的临床前综合征是否存在。在早期甚至临床前阶段识别痴呆对治疗具有重要意义。
对647名年龄在75岁及以上的社区居民样本进行随访,平均随访时间为3.19年(范围为2.61至4.51年)。要求每位受试者参加医学评估,包括标准化病史检查,涵盖过去和当前的健康状况及用药情况;一套神经心理测试(简易精神状态检查、里德记忆测试、语言流畅性、波士顿命名测试的子集和相似性、画钟测试和临摹图)以及体格检查。利用认知、运动和血管特征定义三种主要痴呆(阿尔茨海默病、血管性痴呆和帕金森病及相关痴呆)及其组合的临床前综合征。检查其由死亡和痴呆发病率定义的纵向结局。
临床前综合征影响了55.7%(n = 299)的受试者。临床前综合征显示出死亡几率增加的趋势(优势比1.72,p = 0.056)以及患痴呆几率显著增加(优势比4.81,p < 0.001)。临床前综合征具有高度敏感性,在58例新发痴呆病例中检测出52例(89.7%)。在268例临床前受试者中,216例(80.6%)在3年期间未出现痴呆(阳性预测值19.4%)。被定义为具有认知、锥体外系和血管特征组合的受试者进展为痴呆的风险最大。
临床前综合征是痴呆的敏感且显著的预测指标。鉴于其阳性预测值较低,本研究中定义的临床前综合征仍是一种需要在定义上进一步完善并进行更长观察期的研究工具。多种共存的临床前疾病导致痴呆发病率更高,为多种疾病之间的累加作用提供了证据。